A  ||| S:0 E:2 ||| DT
systematic  ||| S:2 E:13 ||| JJ
comparison  ||| S:13 E:24 ||| NN
of  ||| S:24 E:27 ||| IN
rheumatoid  ||| S:27 E:38 ||| JJ
arthritis  ||| S:38 E:48 ||| NN
and  ||| S:48 E:52 ||| CC
ankylosing  ||| S:52 E:63 ||| NNS
spondylitis  ||| S:63 E:75 ||| VBP
The  ||| S:75 E:79 ||| DT
clinical  ||| S:79 E:88 ||| JJ
manifestations  ||| S:88 E:103 ||| NNS
of  ||| S:103 E:106 ||| IN
rheumatoid  ||| S:106 E:117 ||| JJ
arthritis  ||| S:117 E:127 ||| NN
( ||| S:127 E:128 ||| -LRB-
RA ||| S:128 E:130 ||| NNP
)  ||| S:130 E:132 ||| -RRB-
and  ||| S:132 E:136 ||| CC
ankylosing  ||| S:136 E:147 ||| JJ
spondylitis  ||| S:147 E:159 ||| NNS
( ||| S:159 E:160 ||| -LRB-
AS ||| S:160 E:162 ||| NNP
)  ||| S:162 E:164 ||| -RRB-
differ  ||| S:164 E:171 ||| VBP
in  ||| S:171 E:174 ||| IN
many  ||| S:174 E:179 ||| JJ
ways ||| S:179 E:183 ||| NNS
.  ||| S:183 E:185 ||| .
The  ||| S:185 E:189 ||| DT
age  ||| S:189 E:193 ||| NN
of  ||| S:193 E:196 ||| IN
onset  ||| S:196 E:202 ||| NN
in  ||| S:202 E:205 ||| IN
AS  ||| S:205 E:208 ||| NNP
is  ||| S:208 E:211 ||| VBZ
much  ||| S:211 E:216 ||| RB
younger ||| S:216 E:223 ||| JJR
,  ||| S:223 E:225 ||| ,
with  ||| S:225 E:230 ||| IN
an  ||| S:230 E:233 ||| DT
average  ||| S:233 E:241 ||| JJ
onset  ||| S:241 E:247 ||| NN
of  ||| S:247 E:250 ||| IN
28  ||| S:250 E:253 ||| CD
years  ||| S:253 E:259 ||| NNS
compared  ||| S:259 E:268 ||| VBN
with  ||| S:268 E:273 ||| IN
40-50  ||| S:273 E:279 ||| CD
years  ||| S:279 E:285 ||| NNS
in  ||| S:285 E:288 ||| IN
RA ||| S:288 E:290 ||| NNP
,  ||| S:290 E:292 ||| ,
and  ||| S:292 E:296 ||| CC
with  ||| S:296 E:301 ||| IN
a  ||| S:301 E:303 ||| DT
male  ||| S:303 E:308 ||| JJ
predominance  ||| S:308 E:321 ||| NNS
( ||| S:321 E:322 ||| -LRB-
3 ||| S:322 E:323 ||| LS
: ||| S:323 E:324 ||| :
1 ||| S:324 E:325 ||| LS
)  ||| S:325 E:327 ||| -RRB-
compared  ||| S:327 E:336 ||| VBN
with  ||| S:336 E:341 ||| IN
the  ||| S:341 E:345 ||| DT
female  ||| S:345 E:352 ||| JJ
predominance  ||| S:352 E:365 ||| NN
in  ||| S:365 E:368 ||| IN
RA ||| S:368 E:370 ||| NNP
.  ||| S:370 E:372 ||| .
The  ||| S:372 E:376 ||| DT
genetic  ||| S:376 E:384 ||| JJ
association  ||| S:384 E:396 ||| NN
with  ||| S:396 E:401 ||| IN
HLA  ||| S:401 E:405 ||| NNP
alleles  ||| S:405 E:413 ||| NN
is  ||| S:413 E:416 ||| VBZ
stronger  ||| S:416 E:425 ||| JJR
in  ||| S:425 E:428 ||| IN
AS ||| S:428 E:430 ||| NNP
,  ||| S:430 E:432 ||| ,
with  ||| S:432 E:437 ||| IN
an  ||| S:437 E:440 ||| DT
HLA-B27  ||| S:440 E:448 ||| JJ
antigen  ||| S:448 E:456 ||| NN
in  ||| S:456 E:459 ||| IN
95 ||| S:459 E:461 ||| CD
%  ||| S:461 E:463 ||| NN
of  ||| S:463 E:466 ||| IN
the  ||| S:466 E:470 ||| DT
patients  ||| S:470 E:479 ||| NNS
compared  ||| S:479 E:488 ||| VBN
with  ||| S:488 E:493 ||| IN
RA ||| S:493 E:495 ||| NNP
,  ||| S:495 E:497 ||| ,
with  ||| S:497 E:502 ||| IN
60 ||| S:502 E:504 ||| CD
%  ||| S:504 E:506 ||| NN
HLA  ||| S:506 E:510 ||| NNP
DR4  ||| S:510 E:514 ||| NNP
or  ||| S:514 E:517 ||| CC
DR  ||| S:517 E:520 ||| NNP
1  ||| S:520 E:522 ||| CD
positives ||| S:522 E:531 ||| NNS
.  ||| S:531 E:533 ||| .
The  ||| S:533 E:537 ||| DT
type  ||| S:537 E:542 ||| NN
and  ||| S:542 E:546 ||| CC
localisation  ||| S:546 E:559 ||| NN
of  ||| S:559 E:562 ||| IN
arthritis  ||| S:562 E:572 ||| NN
is  ||| S:572 E:575 ||| VBZ
peripheral  ||| S:575 E:586 ||| JJ
polyarthritis  ||| S:586 E:600 ||| NN
in  ||| S:600 E:603 ||| IN
RA ||| S:603 E:605 ||| NNP
,  ||| S:605 E:607 ||| ,
especially  ||| S:607 E:618 ||| RB
with  ||| S:618 E:623 ||| IN
involvement  ||| S:623 E:635 ||| NN
of  ||| S:635 E:638 ||| IN
hands  ||| S:638 E:644 ||| NNS
and  ||| S:644 E:648 ||| CC
feet ||| S:648 E:652 ||| NNS
,  ||| S:652 E:654 ||| ,
whereas  ||| S:654 E:662 ||| VBG
in  ||| S:662 E:665 ||| RP
AS  ||| S:665 E:668 ||| IN
the  ||| S:668 E:672 ||| DT
arthritis  ||| S:672 E:682 ||| NN
is  ||| S:682 E:685 ||| VBZ
mainly  ||| S:685 E:692 ||| RB
localized  ||| S:692 E:702 ||| VBN
in  ||| S:702 E:705 ||| IN
the  ||| S:705 E:709 ||| DT
spine  ||| S:709 E:715 ||| NN
and  ||| S:715 E:719 ||| CC
sacroiliac  ||| S:719 E:730 ||| JJ
joints  ||| S:730 E:737 ||| NNS
with  ||| S:737 E:742 ||| IN
an  ||| S:742 E:745 ||| DT
oligoarthritis  ||| S:745 E:760 ||| NN
of  ||| S:760 E:763 ||| IN
the  ||| S:763 E:767 ||| DT
larger  ||| S:767 E:774 ||| JJR
joints  ||| S:774 E:781 ||| NNS
( ||| S:781 E:782 ||| -LRB-
hips ||| S:782 E:786 ||| UH
,  ||| S:786 E:788 ||| ,
knees ||| S:788 E:793 ||| NNS
,  ||| S:793 E:795 ||| ,
shoulders ||| S:795 E:804 ||| NNS
) ||| S:804 E:805 ||| -RRB-
.  ||| S:805 E:807 ||| .
The  ||| S:807 E:811 ||| DT
radiographic  ||| S:811 E:824 ||| JJ
signs  ||| S:824 E:830 ||| NNS
in  ||| S:830 E:833 ||| IN
RA  ||| S:833 E:836 ||| NNP
show  ||| S:836 E:841 ||| NN
bone  ||| S:841 E:846 ||| NN
resorption  ||| S:846 E:857 ||| NN
with  ||| S:857 E:862 ||| IN
erosive  ||| S:862 E:870 ||| JJ
changes  ||| S:870 E:878 ||| NNS
in  ||| S:878 E:881 ||| IN
contrast  ||| S:881 E:890 ||| NN
with  ||| S:890 E:895 ||| IN
AS  ||| S:895 E:898 ||| NNP
where  ||| S:898 E:904 ||| WRB
bone  ||| S:904 E:909 ||| JJ
formation  ||| S:909 E:919 ||| NN
with  ||| S:919 E:924 ||| IN
vertebral  ||| S:924 E:934 ||| JJ
sydesmophytes  ||| S:934 E:948 ||| NN
is  ||| S:948 E:951 ||| VBZ
present ||| S:951 E:958 ||| JJ
.  ||| S:958 E:960 ||| .
Extra-articular  ||| S:960 E:976 ||| JJ
manifestations  ||| S:976 E:991 ||| NNS
can  ||| S:991 E:995 ||| MD
occur  ||| S:995 E:1001 ||| VB
in  ||| S:1001 E:1004 ||| IN
both  ||| S:1004 E:1009 ||| DT
diseases  ||| S:1009 E:1018 ||| NNS
but  ||| S:1018 E:1022 ||| CC
again  ||| S:1022 E:1028 ||| RB
these  ||| S:1028 E:1034 ||| DT
manifestations  ||| S:1034 E:1049 ||| NNS
differ  ||| S:1049 E:1056 ||| VBP
in  ||| S:1056 E:1059 ||| IN
the  ||| S:1059 E:1063 ||| DT
eye  ||| S:1063 E:1067 ||| NN
( ||| S:1067 E:1068 ||| -LRB-
keratoconjuctivitis  ||| S:1068 E:1088 ||| JJ
sicca  ||| S:1088 E:1094 ||| NN
and  ||| S:1094 E:1098 ||| CC
scleritis  ||| S:1098 E:1108 ||| NN
in  ||| S:1108 E:1111 ||| IN
RA ||| S:1111 E:1113 ||| NNP
,  ||| S:1113 E:1115 ||| ,
versus  ||| S:1115 E:1122 ||| FW
anterior  ||| S:1122 E:1131 ||| FW
uveitis  ||| S:1131 E:1139 ||| FW
in  ||| S:1139 E:1142 ||| IN
AS ||| S:1142 E:1144 ||| NNP
) ||| S:1144 E:1145 ||| -RRB-
,  ||| S:1145 E:1147 ||| ,
heart  ||| S:1147 E:1153 ||| NN
( ||| S:1153 E:1154 ||| -LRB-
pericarditis  ||| S:1154 E:1167 ||| NN
in  ||| S:1167 E:1170 ||| IN
RA ||| S:1170 E:1172 ||| NNP
,  ||| S:1172 E:1174 ||| ,
conduction  ||| S:1174 E:1185 ||| JJ
disturbances  ||| S:1185 E:1198 ||| NNS
in  ||| S:1198 E:1201 ||| IN
AS ||| S:1201 E:1203 ||| NNP
) ||| S:1203 E:1204 ||| -RRB-
,  ||| S:1204 E:1206 ||| ,
lungs  ||| S:1206 E:1212 ||| NNS
( ||| S:1212 E:1213 ||| -LRB-
pleural  ||| S:1213 E:1221 ||| JJ
lesions  ||| S:1221 E:1229 ||| NNS
or  ||| S:1229 E:1232 ||| CC
nodules  ||| S:1232 E:1240 ||| NN
in  ||| S:1240 E:1243 ||| IN
RA  ||| S:1243 E:1246 ||| NNP
and  ||| S:1246 E:1250 ||| CC
fibrosis  ||| S:1250 E:1259 ||| NN
in  ||| S:1259 E:1262 ||| IN
AS ||| S:1262 E:1264 ||| NNP
)  ||| S:1264 E:1266 ||| -RRB-
and  ||| S:1266 E:1270 ||| CC
gastrointestinal  ||| S:1270 E:1287 ||| JJ
tract  ||| S:1287 E:1293 ||| NN
( ||| S:1293 E:1294 ||| -LRB-
peptic  ||| S:1294 E:1301 ||| JJ
ulcers  ||| S:1301 E:1308 ||| NNS
in  ||| S:1308 E:1311 ||| IN
RA  ||| S:1311 E:1314 ||| NNP
and  ||| S:1314 E:1318 ||| CC
colitis  ||| S:1318 E:1326 ||| NN
in  ||| S:1326 E:1329 ||| IN
AS ||| S:1329 E:1331 ||| NNP
) ||| S:1331 E:1332 ||| -RRB-
.Both  ||| S:1332 E:1338 ||| CD
diseases  ||| S:1338 E:1347 ||| NNS
respond  ||| S:1347 E:1355 ||| VBP
well  ||| S:1355 E:1360 ||| RB
to  ||| S:1360 E:1363 ||| TO
treatment  ||| S:1363 E:1373 ||| NN
with  ||| S:1373 E:1378 ||| IN
NSAIDs  ||| S:1378 E:1385 ||| JJ
but  ||| S:1385 E:1389 ||| CC
DMARDs ||| S:1389 E:1395 ||| JJ
,  ||| S:1395 E:1397 ||| ,
which  ||| S:1397 E:1403 ||| WDT
are  ||| S:1403 E:1407 ||| VBP
very  ||| S:1407 E:1412 ||| RB
important  ||| S:1412 E:1422 ||| JJ
in  ||| S:1422 E:1425 ||| IN
RA ||| S:1425 E:1427 ||| NNP
,  ||| S:1427 E:1429 ||| ,
have  ||| S:1429 E:1434 ||| VBP
limited  ||| S:1434 E:1442 ||| JJ
value  ||| S:1442 E:1448 ||| NN
in  ||| S:1448 E:1451 ||| IN
AS ||| S:1451 E:1453 ||| NNP
.  ||| S:1453 E:1455 ||| .
TNF  ||| S:1455 E:1459 ||| NNP
alfa  ||| S:1459 E:1464 ||| VBZ
blocking  ||| S:1464 E:1473 ||| VBG
drugs ||| S:1473 E:1478 ||| NNS
,  ||| S:1478 E:1480 ||| ,
however ||| S:1480 E:1487 ||| RB
,  ||| S:1487 E:1489 ||| ,
show  ||| S:1489 E:1494 ||| VBP
a  ||| S:1494 E:1496 ||| DT
high  ||| S:1496 E:1501 ||| JJ
efficacy  ||| S:1501 E:1510 ||| NN
in  ||| S:1510 E:1513 ||| IN
both  ||| S:1513 E:1518 ||| DT
diseases ||| S:1518 E:1526 ||| NNS
.  ||| S:1526 E:1528 ||| .
